Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Experimental peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Proposed membrane HDM-2 targeting.
Evidence and critical reading
Reported scientific and empirical uses
Oncology research
Promoted as an anticancer agent; handbook regimens are not validated oncology treatment.
Human evidence
The cited cell studies and mouse leukemia models do not establish clinical cancer-treatment effectiveness or safety in people.
Preclinical evidence
PNC-27 is an experimental peptide with reported anticancer activity in cell studies and mouse leukemia models. These findings do not establish effectiveness or safety in people, or a validated human dosing regimen. Selectivity depends on the experimental system and should not be interpreted as proof that normal human tissues are spared. Scientific/expert review pending.
Critical reading and limitations
Human-derived cells in mouse AML models are not treated patients (Wang et al., Leukemia 2020, first online 2019; PMID 31337857). PNC-27 is distinct from PNC-28 and engineered variants. Yang et al. (JBC 2010; PMID 20484051) provides preferential-cytotoxicity context, not universal protection of normal cells; experiments with other engineered peptides are not attributed to PNC-27. The AML abstract and bibliography were reviewed, not the full supplements.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Toxicity, specificity and interactions unresolved. FDA contamination finding is a product-quality issue distinct from molecular efficacy.
Toxicity uncertainty and regulatory alerts preclude claims of established safety/therapeutic dosing.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
PNC-27 · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
The chapter describes oncology use with quantities and units requiring independent verification. It is not converted into a patient treatment schedule. · manual01 · Page 109
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID20484051
- PMID31337857
Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia.
- PMID20080680
Sarafraz-Yazdi E, Bowne WB, Adler V, Sookraj KA, Wu V, Shteyler V, Patel H, Oxbury W, Brandt-Rauf P, Zenilman ME, Michl J, Pincus MR.
October 16, 2026
- R38
- R39
- manual01
Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
James B. LaValle; Gordon Crozier; Joseph P. Cleaver; Andrew Heyman
October 16, 2026
Bibliographic attribution only. The supplied handbook is a secondary empirical practice source, not clinical verification. Private source files and supplier/download destinations are not provided here.
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026